The role of post-operative cetuximab-based bioradiotherapy in high risk head and neck carcinomas.

The role of post-operative cetuximab-based bioradiotherapy in high risk head and neck carcinomas. - Post-operative bioradiotherapy in high risk head and neck carcinomas

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017634

Enrollment

Registered

2015-05-20

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck squamous cell carcinomas

Interventions

Cetuximab-based Bioradiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The cases pathologically diagnosed as squamous cell carcinomas The cases of over than stage 3 The cases with the following risk factors after the surgery 1. tumor cell in surgical margins. 2. Less than 5mm of sugical margin. 3. Extra capsular spread of lymph node metastasis 4. Perineural invasion 5. vessel or ductal invasion, or tumor thrombosis

Exclusion criteria

Exclusion criteria: The cases with a history of Interstitial pneumonia. The cases with a history of irradiation on head and neck region. The cases that researchers regard as inadequate.

Design outcomes

Primary

Measure	Time frame
Completion rate of this treatment Probability of adverse effect	—

Secondary

Measure	Time frame
Overall survival rate Disease free survival rate Loco-regional control rate Probability of distant metastasis	—

Countries

Japan

Contacts

Public ContactTomohiro Sakashita

Hokkaido University Graduate school of Medicine. Department of Otolaryngology- Head and Neck Surgery.

t-sakashita@med.hokudai.ac.jp011-707-5958

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026